Q1 Earnings Estimate for ONCY Issued By HC Wainwright

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Oncolytics Biotech in a report released on Friday, April 10th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.02) per share for the quarter. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at ($0.02) EPS, Q4 2027 earnings at ($0.02) EPS and FY2030 earnings at $0.18 EPS.

A number of other analysts have also weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Friday, March 27th. Wall Street Zen raised shares of Oncolytics Biotech from a “strong sell” rating to a “hold” rating in a research report on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Oncolytics Biotech Trading Up 12.9%

Shares of NASDAQ ONCY opened at $1.05 on Monday. Oncolytics Biotech has a 12-month low of $0.33 and a 12-month high of $1.51. The stock has a market capitalization of $121.94 million, a price-to-earnings ratio of -3.62 and a beta of 0.98. The firm’s 50-day moving average price is $0.97 and its 200-day moving average price is $1.04.

Oncolytics Biotech (NASDAQ:ONCY) last announced its earnings results on Monday, March 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02).

Insider Activity

In other news, Director Bernd R. Seizinger acquired 40,000 shares of Oncolytics Biotech stock in a transaction that occurred on Thursday, February 12th. The shares were bought at an average cost of $0.85 per share, with a total value of $34,000.00. Following the transaction, the director directly owned 566,991 shares of the company’s stock, valued at $481,942.35. This trade represents a 7.59% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Wayne Pisano acquired 30,000 shares of Oncolytics Biotech stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average cost of $0.84 per share, for a total transaction of $25,200.00. Following the completion of the transaction, the director directly owned 492,414 shares in the company, valued at $413,627.76. This trade represents a 6.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 404,282 shares of company stock valued at $363,232. Company insiders own 0.10% of the company’s stock.

Hedge Funds Weigh In On Oncolytics Biotech

A number of institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new position in shares of Oncolytics Biotech during the third quarter worth approximately $535,000. Connective Capital Management LLC purchased a new position in shares of Oncolytics Biotech during the fourth quarter worth approximately $131,000. XTX Topco Ltd purchased a new position in shares of Oncolytics Biotech during the fourth quarter worth approximately $69,000. Virtu Financial LLC purchased a new position in shares of Oncolytics Biotech during the fourth quarter worth approximately $68,000. Finally, Tocqueville Asset Management L.P. purchased a new position in shares of Oncolytics Biotech during the fourth quarter worth approximately $63,000. 6.82% of the stock is owned by hedge funds and other institutional investors.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.